Kohei Shitara, MD

Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials

Background Results in the IDEA Collaboration have allowed clinical practice guidelines to prioritise 3-months (3m) of CAPOX for the ad...

Takeharu Yamanaka ;

Kohei Shitara , MD;

Takayuki Yoshino , MD, PhD;

06/30/2020

Emerging Concepts in HER2-Driven Gastrointestinal Cancers

Kohei Shitara , MD;

Josep Tabernero , MD, PhD;

Salvatore Siena , MD;

Eric Van Cutsem , MD, PhD;

08/16/2019

New Targets and Agents in Upper GI Cancer

Kohei Shitara , MD;

07/06/2023

Kohei Shitara, MD, PhD, National Cancer Center Hospital East

Videos

Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer

11/14/2023

Kohei Shitara , MD;

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study,...

11/14/2023

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 5

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar